Signal Transduction and Targeted Therapy

Article	Citations
Greasy hair against obesity	2103
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	1713
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1386
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	1307
Moving towards precision psychiatry: the hard nut of depression	1278
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	1121
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	1078
Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	1073
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	1033
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	1027
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	946
Dopamine as a teaching signal: understanding its role in shaping individual behavior	935
Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry	924
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	881
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	851
Correction: Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine	849
Animal models for COVID-19: advances, gaps and perspectives	849
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	834
Identification of glutamine as a potential therapeutic target in dry eye disease	822
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	814
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	803
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	790
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	782
Sensory neurons: unveiling the symphony of wound healing	756
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	748

Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	697
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	676
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	642
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	639
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT	630
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	628
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance	613
Correction: The Hippo signalling pathway and its implications in human health and diseases	610
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	607
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	586
Neutrophil extracellular traps in homeostasis and disease	580
PD-1 and LAG-3: synergistic fostering of T cell exhaustion	578
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	576
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	574
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	572
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	572
Signal pathways of melanoma and targeted therapy	571
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	569
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	567
Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	549
Phototherapy in cancer treatment: strategies and challenges	534
“Good” fats, bad news: HDL-delivered vitamin E shields tumors from ferroptosis	530
Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection	519
Top(ological-operon) secret behind the long-range transcriptional coupling	517
Omicron spike protein: a clue for viral entry and immune evasion	515
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	512
Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer’s disease therapy	511
SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes	489
PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron	481
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	477
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	469
Escaping alveolar macrophage endosomal retention explains massive expansion of SARS-CoV-2 delta variant	466
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	461
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	451
Beyond borders: the choroid plexus-immune communication during neuroinflammation	449
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination	445
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	440
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	431
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	425
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	418
Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver	417
Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects	410
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)	406
Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	401
Platelets and diseases: signal transduction and advances in targeted therapy	400
The RING finger protein family in health and disease	387
Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair	383
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	379
Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis	363
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	359

Harnessing innate immune pathways for therapeutic advancement in cancer	358
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	354
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	345
Mind-body control: a new perspective on motor neuron function	337
Microbiota in health and diseases	337
Base editing: a promising tool to rescue spinal muscular atrophy	331
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	331
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	327
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	326
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	324
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	315
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease	311
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	309
sRAGE alleviates SARS-CoV-2-induced pneumonia in hamster	306
Nascent mRNA damage: depot and disposal	305
Persistent SARS-CoV-2 infection in asymptomatic young adults	303
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance	299
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	294
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	294
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	293
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies	292
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	290
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	288
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy	288
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	286
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	286
Molecular insights of exercise therapy in disease prevention and treatment	285
Small molecules in the treatment of COVID-19	281
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	280
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	279
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	275
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	273
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	273
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	271
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	267
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	263
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	260
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	255
Mitochondrial heterogeneity in diseases	255
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	254
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	253
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	252
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	247
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	246
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	246
Lactate metabolism in human health and disease	246
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	245
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	243
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	242
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities	241
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	236
Targeting PI3K/Akt signal transduction for cancer therapy	236
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	235
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	229
Single-cell genomics: the human biomolecular and cell atlases	227
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	227
Current landscape of innovative drug development and regulatory support in China	220
Back to pluripotency: fully chemically induced reboot of human somatic cells	220
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	218
Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer	217
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	216
Pulsed electromagnetic fields inhibit atherosclerosis by regulating pyroptosis through membrane tension-mediated mechanosensitive channels	214
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	214
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	213
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	212
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	211
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer	208
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	207
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	207
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	207
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	205
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	203
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	202
Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice	196
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	195
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	195
Mutually exclusive epigenetic modification on SIX6 with hypermethylation for precancerous stage and metastasis emergence tracing	192
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	191
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	188
Programmable synthetic receptors: the next-generation of cell and gene therapies	187

Glioblastoma at the crossroads: current understanding and future therapeutic horizons	186
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	186
RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	185
mRNA-based therapeutics: powerful and versatile tools to combat diseases	183
Signaling pathways and targeted therapies for psoriasis	183
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	179
Deconstructing the intra-tumor subclonal heterogeneity of lung synchronous ground-glass nodules using whole-genome sequencing	177
Activated STING: an ion channel to trigger non-interferon-related functions	172
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	172
Time’s up: mutation rate and lifespan	171
Phenotypic characteristics and T cell receptor properties in melanoma: deciphering the correlation at single-cell resolution	169
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	168
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	167
Intervening pyruvate carboxylase stunts tumor growth by strengthening anti-tumor actions of tumor-associated macrophages	166
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	163
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	162
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	161
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	157
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	156
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	153
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	151
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	149
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	148
Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target	147
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	146
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	146
Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone	145
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	145
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	144
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	142
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	141
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	141
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	141
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	138
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	136
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape	136
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	136
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	135
Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury	135
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	135
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	135
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	135
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	134
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	134
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	133
Signaling pathways in obesity: mechanisms and therapeutic interventions	133
Redox regulation: mechanisms, biology and therapeutic targets in diseases	132
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	132
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	132
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	131
Targeted protein degradation: advances in drug discovery and clinical practice	130
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	129
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates	128
Artificial intelligence in cancer target identification and drug discovery	128
Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic	128
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	126
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial	126
SCGN deficiency is a risk factor for autism spectrum disorder	126
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	126
Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure	126
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	125
The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation	125
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	122
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	122
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	120
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a	120
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	119
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	118
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	118
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	117
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy	115
A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol	114
Hypocretin neuron hyperexcitability in the hypothalamus: a newly discovered culprit in aging-related sleep impairment	114
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	113
The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling	112
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	112
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)	112
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern	111
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	111
NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity	110
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection	110
Uveal melanoma with a GNA11/GNAQ mutation secretes VEGF for systemic spread	110
The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis	108
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	108
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies	108
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial	105
PARP1-DNA co-condensation: the driver of broken DNA repair	104
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression	104
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes	103
Exosomes secreted from cardiomyocytes suppress the sensitivity of tumor ferroptosis in ischemic heart failure	102
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches	102
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	101
Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1	101
The gasdermin family: emerging therapeutic targets in diseases	101
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial	101